ArticleAnalytica chimica acta2025
Deciphering the three-dimensional biomolecular distribution in the Alzheimer's disease brain: A multiomic approach integrating immunohistochemistry with MALDI MS imaging.
Article in Analytica chimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MALDI Mass Spectrometry Imaging in Alzheimer's Disease Lipidomics: Matrix Selection, Spatial Lipid Pathology and Emerging Analytical Strategies.International journal of molecular sciences · 2026Review
- A Multimodal Imaging Pipeline for the Discovery of Molecular Markers of Cellular Neighborhoods.bioRxiv : the preprint server for biology · 2026Article
- ExploringFrontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Alzheimer's disease (AD) is characterized by complex and distinct spatial and molecular changes in the brain that contribute to its onset and progression, which includes disruptions in proteins, lipids, and neuroinflammatory pathways. In this study, we introduce a three-dimensional (3D) spatial multi-omics imaging approach that integrates lipid mass spectrometry imaging (MSI) with targeted proteomic analysis using 10-plex photo-cleavable mass tag (PC-MT) probes. Brain tissues from wild-type (WT) and AD model mice were sectioned at four coronal levels, spaced 1500 μm apart, enabling the reconstruction of a depth-resolved molecular atlas. Lipid MSI revealed region- and depth-specific alterations in phosphatidylcholine (PC), phosphatidylethanolamine (PE), and other lipid classes between AD and WT brains. In parallel, protein MSI using PC-MT probes identified spatially distinct changes in neuroinflammatory and neurodegenerative markers across the cortex, hippocampus, and thalamus at different depths. This integrative platform uncovered co-localization patterns of lipid dysregulation and protein overexpression unique to AD pathology, highlighting vulnerable brain subregions. Our findings demonstrate that combining targeted protein and untargeted lipid imaging in 3D enables the discovery of spatially coordinated molecular signatures in neurodegeneration, offering a powerful framework for biomarker discovery and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.